JBS Logo
JBS Logo
JBS

JBS Entering Cultivated Protein Market with Acquisition of BioTech Foods

The company also announced a new production plant in Spain that will scale up production. The company is also going to build a research and development center in biotechnology and cultivated protein in Brazil.

Subscribe
November 22, 2021

SÃO PAULO — JBS, a global protein company, has entered into an agreement to acquire control of Spanish company BioTech Foods. The deal signals the company's entry into the cultivated protein market, which consists of producing food from animal cells and includes investment in building a new plant in Spain to scale up production. Along with the acquisition, JBS is also announcing the setting up of Brazil's first cultivated protein research and development center. In all, JBS will channel $100 million into the two projects.

Founded in 2017, BioTech Foods is one of the leaders in the development of biotechnology for producing cultivated protein, and has the support of the Spanish government and the European Union. The company operates a pilot plant in the city of San Sebastián and expects to reach commercial production in mid-2024 with the building of this new production facility. The investment in the new facilities is estimated at $41 million.

BioTech Foods was founded by Iñigo Charola, a sales executive with broad experience in marketing and strategy, and Mercedes Vila Juárez, Ph.D., an expert in materials physics and one of the world's leading experts in the use of materials for biomedicine. In 2010, she was awarded with the Lóreal-UNESCO Award "For Women in Science" in recognition of her scientific career. Charola is BioTech's CEO and Mercedes is chief technology officer.

Under the terms of the deal, JBS becomes the majority shareholder of BioTech Foods. The deal enables both companies to pool their strengths and accelerate the development of the cultivated protein market. JBS will have access to BioTech Foods technology and protein production capability while providing the industrial processing capacity, marketing structure and sales channels to bring the new product to market.

When commercial operations begin, the cultivated protein will reach consumers in the form of prepared foods, such as hamburgers, steaks, sausage meats and meatballs, among others, with the same quality, safety, taste and texture as traditional protein. The technology has the potential not only for the production of beef protein, but also chicken, pork and fish.

"This acquisition strengthens our strategy of innovation, from how we develop new products to how we commercialize them, to address the growing global demand for food. Combining technological know-how with our production capacity, we will be in a position to accelerate the development of the cultivated protein market," said Gilberto Tomazoni, global CEO of JBS.

The acquisition of BioTech Foods is still subject to confirmation by the foreign investment authority of Spain, among other conditions common to this type of transaction.

The initiative in Europe is being supplemented by the cultivated protein research center in Brazil. Due to be inaugurated in 2022, the second phase of the center will include a plant occupying an area of 10,000 square meters. Headed up by Luismar Marques Porto and Fernanda Vieira Berti, both Ph.D.s in chemical engineering, the initiative will have around 25 researchers and will work on the development of leading-edge technologies for the food industry.

Two of Brazil's major specialists in bioengineering, both professors have international professional and academic experience. While Porto was a visiting scientist at Harvard University and the Massachusetts Institute of Technology (MIT), Fernanda has been at the Research Institute I3Bs and created a startup incubated in Silicon Valley, which operates in Europe developing products based on regenerative and T-cell medicine for treating animals.

Through the investment in the R&D center, JBS intends to develop new techniques that accelerate the economies of scale and reduce the costs of producing cultivated protein, bringing forward its commercialization on the market.

"We are expanding our global platform to address the new trends in consumption and the growth of the global population. The acquisition of BioTech Foods and the new research center put JBS in a unique position to push ahead in the cultivated protein sector," said Tomazoni.